Respironics Announces Offer for Profile Therapeutics

In a move that will expand its presence in the international respiratory and sleep market, Respironics, Inc. (Murrysville, PA, USA) has announced that it will make an offer to acquire Profile Therapeutics plc (London, UK) for around U.S.$44.6 million.

Profile Therapeutics, currently Respironics' distributor for sleep and ventilation products in the United Kingdom, had revenues of about $23.9 million over the last 12 months. The company distributes, develops, and commercializes specialty products to improve the treatment of sleep and respiratory patients. Following the acquisiton, Profile Therapeutics would become a wholly owned subsidiary of Respironics. The acquisition has been approved by the boards of both companies.

Profile Therapeutics core respiratory delivery system is an innovative platform that utilizes "intelligent inhalation” technology called Adaptive Aerosol Delivery (AAD). This delivery system is designed to automatically respond to an individual patient's breathing patterns in order to deliver a precise dose synchronized with the patient's inhalation cycle. The technology may help patients by ensuring a uniform drug dose and reproducible therapy while also allowing for smaller fill volumes of drug, compared to conventional nebulizers.

"This opportunity is consistent with our strategic plan, which calls for expanding our presence in the international sleep and respiratory markets, and enhances the breadth of our products and services,” said John Miclot, president of Respironics.




Related Links:
Respironics
Profile Therapeutics